Pharmacodynamic separation of gemcitabine and erlotinib in locally advanced or metastatic pancreatic cancer: therapeutic and biomarker results

Abstract

Purpose: Erlotinib marginally improves survival when administered continuously with gemcitabine to patients with advanced pancreatic cancer; however, preclinical data suggest that there is antagonism between chemotherapy and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors when these are delivered concurrently. We tested a pharmacodynamic separation approach for erlotinib plus gemcitabine and interrogated EGFR signaling intermediates as potential surrogates for the efficacy of this strategy.

Methods: Patients with measurable, previously untreated locally advanced unresectable or metastatic pancreatic cancer were treated with gemcitabine 1000 mg/m(2) as an intravenous infusion over 30-min on days 1, 8, 15 and erlotinib 150 mg/day on days 2-5, 9-12, 16-26 of each 28-day cycle. The primary endpoint was progression-free survival (PFS); secondary endpoints included RECIST objective response rate (ORR) and safety. The study was terminated after thirty patients due to funding considerations.

Results: The median PFS was 2.07 months (95% CI; 1.87-5.50 months) and the ORR was 11%. No unexpected safety signals were seen: the most common grade 3 or higher adverse events were neutropenia (23%), lymphopenia (23%), and fatigue (13%). Patients with mutant plasma Kirsten rat sarcoma virus (KRAS) had significantly lower median PFS (1.8 vs. 4.6 months, p = 0.014) and overall survival (3.0 vs. 10.5 months, p = 0.003) than those without detected plasma KRAS mutations.

Conclusions: Although pharmacodynamically separated erlotinib and gemcitabine were feasible and tolerable in patients with advanced pancreatic cancer, no signal for increased efficacy was seen in this molecularly unselected cohort. Detection of a KRAS mutation in circulating cell-free DNA was a strong predictor of survival.

Trial registration: ClinicalTrials.gov NCT00810719.

Figures

Figure 1

Fig. 1A Progression free survival of patients treated with pharmacodynamically separated gemcitabine and erlotinib by presence or absence of a detectable mutation in KRAS in pre-treatment cell-free DNA Fig. 1B Overall survival of patients treated with pharmacodynamically separated gemcitabine and erlotinib by presence or absence of a detectable mutation in KRAS in pre-treatment cell-free DNA

Figure 1

Fig. 1A Progression free survival of patients treated with pharmacodynamically separated gemcitabine and erlotinib by presence or absence of a detectable mutation in KRAS in pre-treatment cell-free DNA Fig. 1B Overall survival of patients treated with pharmacodynamically separated gemcitabine and erlotinib by presence or absence of a detectable mutation in KRAS in pre-treatment cell-free DNA